These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 28198142)

  • 1. Therapeutic genome engineering via CRISPR-Cas systems.
    Moreno AM; Mali P
    Wiley Interdiscip Rev Syst Biol Med; 2017 Jul; 9(4):. PubMed ID: 28198142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genome editing revolution: A CRISPR-Cas TALE off-target story.
    Stella S; Montoya G
    Bioessays; 2016 Jul; 38 Suppl 1():S4-S13. PubMed ID: 27417121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing.
    Waryah CB; Moses C; Arooj M; Blancafort P
    Methods Mol Biol; 2018; 1767():19-63. PubMed ID: 29524128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the genome editing tool CRISPR/Cas9 in non-human primates.
    Luo X; Li M; Su B
    Dongwuxue Yanjiu; 2016 Jul; 37(4):214-9. PubMed ID: 27469252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for the CRISPR-Based Therapeutics.
    Li B; Niu Y; Ji W; Dong Y
    Trends Pharmacol Sci; 2020 Jan; 41(1):55-65. PubMed ID: 31862124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 genome editing throws descriptive 3-D genome folding studies for a loop.
    Beagan JA; Phillips-Cremins JE
    Wiley Interdiscip Rev Syst Biol Med; 2016 Jul; 8(4):286-99. PubMed ID: 27265842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A CRISPR reimagining: New twists and turns of CRISPR beyond the genome-engineering revolution.
    Plummer RJ; Guo Y; Peng Y
    J Cell Biochem; 2018 Feb; 119(2):1299-1308. PubMed ID: 28926145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational designs of in vivo CRISPR-Cas delivery systems.
    Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
    Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Anti-CRISPR Story: A Battle for Survival.
    Maxwell KL
    Mol Cell; 2017 Oct; 68(1):8-14. PubMed ID: 28985512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of somatic CRISPR-Cas9 to conditional genome editing in Caenorhabditis elegans.
    Li W; Ou G
    Genesis; 2016 Apr; 54(4):170-81. PubMed ID: 26934570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and future prospects for CRISPR-based tools in bacteria.
    Luo ML; Leenay RT; Beisel CL
    Biotechnol Bioeng; 2016 May; 113(5):930-43. PubMed ID: 26460902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing.
    Liu J; Shui SL
    J Control Release; 2016 Dec; 244(Pt A):83-97. PubMed ID: 27865852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome engineering in ophthalmology: Application of CRISPR/Cas to the treatment of eye disease.
    Hung SSC; McCaughey T; Swann O; Pébay A; Hewitt AW
    Prog Retin Eye Res; 2016 Jul; 53():1-20. PubMed ID: 27181583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes.
    Humphrey SE; Kasinski AL
    J Hematol Oncol; 2015 Apr; 8():31. PubMed ID: 25888285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas-based genome engineering in natural product discovery.
    Tong Y; Weber T; Lee SY
    Nat Prod Rep; 2019 Sep; 36(9):1262-1280. PubMed ID: 30548045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.